Stella Diagnostics Inc. (SLDX)
USD 0.05
(13.69%)
USD 0.05
(13.69%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -5.7 Million USD | -366.48% |
| 2022 | -5.32 Million USD | 48.32% |
| 2021 | -16.33 Million USD | -2775.35% |
| 2020 | -249.03 Thousand USD | 79.88% |
| 2019 | -819.46 Thousand USD | -11.07% |
| 2018 | -737.79 Thousand USD | -13588.31% |
| 2017 | -5386.00 USD | 0.0% |
| 2015 | -44 Thousand USD | 77.63% |
| 2014 | -196.72 Thousand USD | -19891709.91% |
| 2013 | - USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -192.3 Thousand USD | -10.92% |
| 2024 Q1 | -218.1 Thousand USD | 83.64% |
| 2023 Q4 | -1.49 Million USD | -200.77% |
| 2023 FY | - USD | -366.48% |
| 2023 Q1 | -9.33 Million USD | -1045.52% |
| 2023 Q2 | -204.37 Thousand USD | 97.81% |
| 2023 Q3 | -497.17 Thousand USD | -143.27% |
| 2022 Q2 | -370.73 Thousand USD | 60.69% |
| 2022 FY | - USD | 48.32% |
| 2022 Q4 | -814.65 Thousand USD | -25.0% |
| 2022 Q3 | -651.73 Thousand USD | -75.8% |
| 2022 Q1 | -942.99 Thousand USD | 0.0% |
| 2021 Q2 | -440.64 Thousand USD | 0.0% |
| 2021 Q3 | -185.84 Thousand USD | 57.82% |
| 2021 FY | - USD | -2775.35% |
| 2020 Q3 | -43.32 Thousand USD | 94.51% |
| 2020 FY | - USD | 79.88% |
| 2020 Q1 | -3090.00 USD | 0.0% |
| 2020 Q2 | -788.51 Thousand USD | -25418.12% |
| 2019 FY | - USD | -11.07% |
| 2018 FY | - USD | -13588.31% |
| 2018 Q1 | -220.15 Thousand USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2015 FY | - USD | 77.63% |
| 2014 FY | - USD | -19891709.91% |
| 2013 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Bio Medica Corporation | -1.16 Million USD | -390.751% |
| Arrayit Corporation | -3.07 Million USD | -85.457% |
| Atlantic International Corp. | -5.38 Million USD | -5.898% |
| Biocept, Inc. | -30.24 Million USD | 81.127% |
| Bioqual, Inc. | 3.03 Million USD | 288.225% |
| CardioGenics Holdings Inc | -757.37 Thousand USD | -653.58% |
| DermTech, Inc. | -97.89 Million USD | 94.17% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.91 Billion USD | 100.196% |
| HTG Molecular Diagnostics, Inc. | -20.24 Million USD | 71.805% |
| iMD Companies, Inc. | -154.65 Thousand USD | -3590.332% |
| IDenta Corp. | 71.58 Thousand USD | 8072.719% |
| Interpace Biosciences, Inc. | 3.83 Million USD | 248.747% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | 14851.693% |
| InVitro International | 6680.00 USD | 85540.569% |
| Lumos Diagnostics Holdings Limited | -5.43 Million USD | -4.993% |
| Many Bright Ideas Technologies Inc. | -12.13 Thousand USD | -46936.674% |
| Medical Imaging Corp. | -896.74 Thousand USD | -536.463% |
| NovelStem International Corp. | -3.78 Million USD | -50.759% |
| Optigenex Inc. | -1.18 Million USD | -380.94% |
| PharmChem, Inc. | 1.05 Million USD | 641.6% |
| Proteome Sciences plc | -1.13 Million USD | -401.973% |
| Response Genetics, Inc | -19.66 Million USD | 70.978% |
| Rennova Health, Inc. | -234.81 Thousand USD | -2330.607% |
| RushNet, Inc. | -614.85 Thousand USD | -828.261% |
| ScreenPro Security Inc. | -3.43 Million USD | -66.161% |
| StageZero Life Sciences Ltd. | -10.27 Million USD | 44.427% |
| Todos Medical Ltd. | -9.39 Million USD | 39.244% |